Corporate Information

• 16 Apr, 2024
  Spago Nanomedical strengthens management with Head of CMC & Supply
• 16 Apr, 2024
  Spago Nanomedical stärker ledningen med chef för CMC & Supply
• 18 Jan, 2024
  Spago Nanomedical presenterar på Redeyes temadag Fight Cancer den 24 januari
• 18 Jan, 2024
  Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24
• 10 Jan, 2024
  Spago Nanomedical går vidare till nästa dosnivå i fas I/IIa-studien Tumorad-01
• 10 Jan, 2024
  Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01
• 15 Dec, 2023
  Spago Nanomedical rapporterar positiva topline-data från den kliniska fas 2a studien SPAGOPIX-02 i patienter med endometrios
• 15 Dec, 2023
  Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis
• 7 Dec, 2023
  Första patienten doserad i Spago Nanomedicals kliniska fas I/IIa-studie inom Tumorad®-programmet
• 7 Dec, 2023
  First patient dosed in Spago Nanomedical’s clinical phase I/IIa study within the Tumorad® program